Research programme: integrin alpha-11 inhibitors - Hansa Medical/Alere

Drug Profile

Research programme: integrin alpha-11 inhibitors - Hansa Medical/Alere

Alternative Names: Anti-α-11

Latest Information Update: 19 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cartela
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 04 Mar 2011 Preclinical development is ongoing in Sweden
  • 19 Jul 2010 Inverness Medical Innovations is now called Alere
  • 04 Jul 2007 Preclinical trials in Rheumatoid arthritis in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top